Ann: Quarterly Activities Report, page-19

You raise many good points "in hindsight" which is fantastic if you chose to live that way.... The 2 rounds of mice trials have no doubt given them the confidence to put BIT225 forward, enlighten us to how long these specific COVID animal testings have been around? Expecting Biotron to throw their golden child treatment in the ring for expensive COVID trials and to jeopardise HIV without solid foundations for success is not understanding the complexities of biotech. Also during the peak of COVID it would not have been prudent to be running further expensive HIV trials. Yes management have been slow & lacking on partner front, with many questions no doubt... but prudent at the same time while dealing with the headwinds of COVID and limited resources. I am interested in the present situation and the general "timelines" that are given are all they can do without a crystal ball.